Impax Labs (NASDAQ:IPXL) Price Target & New Coverage by Leerink Partners
Leerink Partners started its coverage on Impax Labs (NASDAQ:IPXL), today Wednesday, 3 January. Investment firm finds the stock of IPXL attractive and has target price of $22.0 with Outperform rating.
According to data compiled by Thomson Reuters, Impax Labs (NASDAQ:IPXL)’s stock is covered by 14 equity analysts across the Street, with 3 analysts giving it a Sell rating, 5 a Buy rating, while 7 consider it a Hold. The 12-month consensus target price for the stock is $35.79, which reflects an upside potential of 109.30% over the current price.
Krensavage Asset Management Llc had the biggest stake with ownership of 1.03M shares as of q2 2015 for 8.84% of the fund portfolio. Hound Partners Llc is another quite bullish active investment manager who is possessing 6.20M shares of Impax Labs or 3.96% of their fund portfolio. Also, Sivik Global Healthcare Llc have 1.55% of their fund portfolio invested in the company for 130,000 shares. The California-based fund Tradewinds Global Investors Llc revealed it had bought a stake worth about 1.45% of the active investment manager’s stock portfolio in Impax Labs. The Norway-based fund Sector Gamma As is also positive about the stock, possessing 49,661 shares or 1.37% of their fund portfolio.
Impax Labs (NASDAQ:IPXL) Profile
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Impax Labs (NASDAQ:IPXL) traded up 0.88% on 3 January, hitting $17.1. A total of 1.36 million shares of the company’s stock traded hands. This is down from average of 1.58 million shares. Impax Labs has a 52 week low of $7.75 and a 52 week high of $32.2. The company has a market cap of $1.25 billion and a P/E ratio of 0.
Get the latest Impax Labs (NASDAQ:IPXL) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Leerink Partners Starts Coverage on Impax Labs (NASDAQ:IPXL) with Outperform and with $22.0 Target appeared first on Octafinance.